149 related articles for article (PubMed ID: 9325017)
1. In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations.
Behboudi S; Morein B; Villacres-Eriksson M
Cytokine; 1997 Sep; 9(9):682-7. PubMed ID: 9325017
[TBL] [Abstract][Full Text] [Related]
2. In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids.
Behboudi S; Morein B; Villacres-Eriksson M
Clin Exp Immunol; 1996 Jul; 105(1):26-30. PubMed ID: 8697631
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix.
Rönnberg B; Fekadu M; Morein B
Vaccine; 1995 Oct; 13(14):1375-82. PubMed ID: 8585296
[TBL] [Abstract][Full Text] [Related]
4. Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterol-binding capacity and toxicity.
Rönnberg B; Fekadu M; Behboudi S; Kenne L; Morein B
Vaccine; 1997 Dec; 15(17-18):1820-6. PubMed ID: 9413088
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response.
Villacres-Eriksson M; Behboudi S; Morgan AJ; Trinchieri G; Morein B
Cytokine; 1997 Feb; 9(2):73-82. PubMed ID: 9071557
[TBL] [Abstract][Full Text] [Related]
6. The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREP703.
Hu KF; Regner M; Siegrist CA; Lambert P; Chen M; Bengtsson KL; Morein B
FEMS Immunol Med Microbiol; 2005 Feb; 43(2):269-76. PubMed ID: 15681158
[TBL] [Abstract][Full Text] [Related]
7. Iscom, a delivery system for parenteral and mucosal vaccination.
Morein B; Villacrés-Eriksson M; Lövgren-Bengtsson K
Dev Biol Stand; 1998; 92():33-9. PubMed ID: 9554257
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation by iscoms, immune stimulating complexes.
Morein B; Bengtsson KL
Methods; 1999 Sep; 19(1):94-102. PubMed ID: 10525444
[TBL] [Abstract][Full Text] [Related]
9. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms.
Dotsika E; Karagouni E; Sundquist B; Morein B; Morgan A; Villacres-Eriksson M
Scand J Immunol; 1997 Mar; 45(3):261-8. PubMed ID: 9122615
[TBL] [Abstract][Full Text] [Related]
10. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
Cibulski SP; Mourglia-Ettlin G; Teixeira TF; Quirici L; Roehe PM; Ferreira F; Silveira F
Vaccine; 2016 Feb; 34(9):1162-71. PubMed ID: 26826546
[TBL] [Abstract][Full Text] [Related]
11. Quillaja saponin formulations that stimulate proinflammatory cytokines elicit a potent acquired cell-mediated immunity.
Behboudi S; Morein B; Villacres-Eriksson MC
Scand J Immunol; 1999 Oct; 50(4):371-7. PubMed ID: 10520176
[TBL] [Abstract][Full Text] [Related]
12. Isolation and quantification of Quillaja saponaria Molina saponins and lipids in iscom-matrix and iscoms.
Behboudi S; Morein B; Rönnberg B
Vaccine; 1995 Dec; 13(17):1690-6. PubMed ID: 8719521
[TBL] [Abstract][Full Text] [Related]
13. Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix.
Fossum C; Bergström M; Lövgren K; Watson DL; Morein B
Cell Immunol; 1990 Sep; 129(2):414-25. PubMed ID: 2383899
[TBL] [Abstract][Full Text] [Related]
14. Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction.
Villacres MC; Behboudi S; Nikkila T; Lovgren-Bengtsson K; Morein B
Cell Immunol; 1998 Apr; 185(1):30-8. PubMed ID: 9636680
[TBL] [Abstract][Full Text] [Related]
15. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
16. QS-21 and QS-7: purified saponin adjuvants.
Kensil CR; Wu JY; Anderson CA; Wheeler DA; Amsden J
Dev Biol Stand; 1998; 92():41-7. PubMed ID: 9554258
[TBL] [Abstract][Full Text] [Related]
17. Current status and potential application of ISCOMs in veterinary medicine.
Morein B; Hu KF; Abusugra I
Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice.
Fleck JD; Kauffmann C; Spilki F; Lencina CL; Roehe PM; Gosmann G
Vaccine; 2006 Nov; 24(49-50):7129-34. PubMed ID: 16887242
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant activities of saponins from the root of Polygala senega L.
Katselis GS; Estrada A; Gorecki DK; Barl B
Can J Physiol Pharmacol; 2007 Nov; 85(11):1184-94. PubMed ID: 18066120
[TBL] [Abstract][Full Text] [Related]
20. Immunological adjuvants and their modes of action.
Allison AC
Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):141-7. PubMed ID: 9597079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
